Exelixis Inc
—- Market cap
- —
- Debt
- +$399.32M
- Cash
- −$1.06B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXEL stock price vs GTLB: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GTLB's multiple
Needs GTLB P/E.
Implied fair value · at EXEL's multiple
Needs Annual EPS is negative, EXEL P/E.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: EXEL FY 2026 (ended Jan 2, 2026) · GTLB FY 2026 (ended Jan 31, 2026). Fiscal years are not aligned.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Exelixis Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
GITLAB INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.18x
0.11x
Net debt / EBITDA
Leverage against operating earnings
-0.70x
3.61x
Cash and equivalents
Liquid reserves on the balance sheet
$1.06B
$229.58M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
EXEL vs AMGN
BIOGEN INC.
EXEL vs BIIB
GILEAD SCIENCES, INC.
EXEL vs GILD
INCYTE CORP
EXEL vs INCY
Sarepta Therapeutics, Inc.
EXEL vs SRPT
Atlassian Corp
EXEL vs TEAM
Cloudflare, Inc.
EXEL vs NET
PagerDuty, Inc.
EXEL vs PD
ServiceNow, Inc.
EXEL vs NOW
Dynatrace, Inc.
EXEL vs DT
$399.32M
$106.45M
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.